ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• 10 Roadblocks To Traditional Vendor Selection And How ClinAI Solves Them

  Vendor selection in clinical trials is a pivotal process. Explore ten widespread inefficiencies in the current approach and how you can resolve them.

• Unlock Historical Data To Enrich RBM Insights

  The data landscape for clinical operations is complex and comprised of many disparate sources, so a data agnostic solution is essential for full access and visibility into the data. Without an intuitive visual analytics tool, it becomes impossible to navigate data hierarchies and gain meaningful insights into the data.

• Outlook For 2025: New Forces Driving Pragmatic Innovation

  Clinical data trends are evolving rapidly to reduce trial complexity, improve patient experiences, and shorten development timelines.

• Developing Drugs For Rare Diseases: Generating Clinical Evidence

  For rare diseases, scientific breakthroughs often stall before reaching patients. A new approach to generating clinical evidence could change that trajectory.

• Database To Advance Patient-Focused Drug Development With DHTs

  Uncover how the Patient-Focused Digital Measure Report Database resource will leverage patient-reported data to highlight specific indications where DHTs can provide meaningful, patient-centric measures.

• Perspective On The FDA's Final Digital Health Technologies Guidance

  Review the final release of "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations”, where the FDA acknowledges DHT value and the increasing use of them in clinical trials.

• Why ePROs In Oncology Are Perfect For Capturing The Patient's Voice

  Recently released FDA guidance showcases why electronic patient-reported outcomes (ePROs) are ideal for capturing the “voice” of the patient. See how ePRO eases oncology trials.

• What The Joint FDA And EMA's AI Principles Can Mean For Clinical Trial Technology

  New FDA/EMA principles align global expectations for AI in drug trials, emphasizing transparency, human-centric design, and risk-based governance to ensure data integrity and patient safety.

• Will DCTs Finally Democratize Clinical Trials?

  Who wouldn’t rather wear a smartwatch than drive 75 miles to have someone measure their blood pressure? See how DCTs have the capacity to include more people from a broader range of demographics.

• The Hidden Cost Of Preferred Vendors

  Familiar vendors offer comfort — but at the cost of innovation, fit, and fresh thinking. Ease shouldn’t outweigh excellence when selecting partners for your clinical trial.